EVENT DESCRIPTION

In celebration of its 60th anniversary, the Office of Health Economics (OHE) invites you to join us for a seminar considering the Past, Present, and Future of Health Economics followed by a rooftop drinks reception in Washington, D.C.

We will cover three topics critically important to the evolution of health economics and its impact on pharmaceutical policy and practice over the past 60 years. For each we have invited an external expert to provide their perspective followed by one of OHE’s research leaders.

After the seminar, please join us on The Watergate Hotel’s rooftop terrace “Top of the Gate” for drinks and canapes where you will have an opportunity to network with fellow attendees or to ask our speakers further questions.

KEY TOPICS

The Past: The experience of QALYs versus the patient experience. Where have we got to?

The Present: Will the proposed US drug price reforms lower prices, and at what cost?

The Future: Can we speed up high-quality evidence generation for accelerated approvals?

AGENDA

Seminar and Q&A: 17:00-18:30

Rooftop drinks reception: 18:30-21:30

SPEAKERS

Julia Slejko

Julia Slejko is Associate Professor in Department of Pharmaceutical Health Services Research (PHSR) at the University of Maryland School of Pharmacy and is Co-Director of the Patient-Driven Values in Healthcare Evaluation (PAVE) Center. Dr. Slejko’s research is focused on innovative approaches for decision-analytic modeling for economic and health outcomes assessments. She has applied these methods to modeling medication adherence, translating pharmacometric findings to cost-effectiveness analyses and most recently translating patient-driven value elements for economic evaluation. She currently serves as the Co-chair-elect of ISPOR’s Faculty Advisor Council and is Co-lead of the ISPOR Women in HEOR initiative.

Adrian Towse

Professor Adrian Towse is Director Emeritus of the Office of Health Economics in the UK which he led for 25 years. Adrian’s current research includes incentives for new drugs and vaccines to tackle antimicrobial resistance, the use of 'risk-sharing' arrangements between health care payers and pharmaceutical companies, including value-based pricing approaches; the economics of precision or stratified medicine for health care payers and the pharmaceutical industry; and economic issues that affect both R&D for and access to treatments for diseases prevalent in low- and middle-income countries.

Graham Cookson

Professor Graham Cookson is the Chief Executive of the Office of Health Economics.

Graham is an econometrician by training and is interested in the use of big data in health and life sciences research. His current research interests include the measurement and determinants of productivity in healthcare especially labour productivity; the industrial organisation of healthcare especially tariffs and competition; real-world evidence in health economic evaluation; and big data in the health and life sciences. He is best known for this work on the economics of staffing and skill mix in the English NHS, and this research was critical to the development of the NICE Guidelines on Safe Staffing.

Stacie Dusetzina

Dr. Stacie Dusetzina is an associate professor in the Department of Health Policy and an Ingram associate professor of cancer research at Vanderbilt. She is a health services researcher whose work focuses on measuring and evaluating population-level use and costs of medications in the United States. Dr. Dusetzina’s work has contributed to the evidence base for the role of drug costs on patient access to care and policy changes that might improve patient access to high-priced drugs.

She has been recognized for her work at a national level, including being an invited participant for two working group meetings on “Patient Access to Affordable Cancer Drugs,” hosted by the President’s Cancer Panel, and being selected to co-author a National Academies of Sciences, Engineering and Medicine report on the same topic. Dr. Dusetzina’s research has also been broadly covered by The New York Times, NPR, Reuters, The Washington Post, STAT News, ABC News and The Wall Street Journal.

Blythe Adamson

Dr. Blythe Adamson is principal scientist in machine learning at Flatiron Health and founder of Infectious Economics. Following her service as the lead West Wing health economist on the White House COVID-19 Task Force, she designed cost-effective workplace health policies for safe reopening of major sports leagues, Broadway theaters, theme parks, retailers, and universities. At Flatiron, Dr. Adamson analyzes electronic medical records from 2 million cancer patients to assess the value of new medicines and policies.

Dr. Adamson holds degrees in microbiology, epidemiology, and pharmaceutical economics. She has held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling, the HIV Vaccine Trials Network, and Fred Hutchinson Cancer Research Center. Dr. Adamson is currently a member of the International Society for Health Economics and Outcomes Research (ISPOR) Task Force on Machine Learning which will set out good practices for its use in the prediction of risk of various health care events and the causal estimation of treatment effects.

Lotte Steuten

Professor Lotte Steuten is Head of Consulting and Vice President of the Office of Health Economics.

Lotte’s research interest focuses on the development and application of health economic analysis and health technology assessment (HTA), with the aim to accelerate patient access to high value health care services and treatments. She specializes in quantitative methods for estimating and comparing the expected health and economic benefits of new approaches and interventions in disease prevention, diagnostics and treatment, and prioritizing data collection to efficiently build the evidence for new interventions. She is a member of the Board of ISPOR, served on the ISPOR Task Force on good practices in the use of Value of Information techniques and currently on the ISPOR Special Task Force for Value-Based Healthcare.

Patrick Holmes

Patrick Holmes, is a Trustee of the Office of Health Economics. He is also the Science and Innovation Policy Lead at Pfizer Inc, heading up a team with responsibility for developing global health policy initiatives with a focus on market-based R&D incentives, ensuring strong R&D ecosystems, value and innovation frameworks, sustainable patient-centric health systems, and antimicrobial resistance. Patrick represents Pfizer on several health and biopharma working groups, including the Business @ OECD Health Committee, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Value and Access Committee, and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Healthcare Systems Working Group.

Lou Garrison

Lou Garrison, PhD, is Professor Emeritus in The Comparative Health Outcomes, Policy, and Economics Institute in the School of Pharmacy at the University of Washington, where he joined the faculty in 2004.

For the first 13 years of his career, Dr. Garrison worked in non-profit health policy. Following this, he worked as an economist in the pharmaceutical industry for 12 years. From 2002-2004, he was Vice President and Head of Health Economics & Strategic Pricing in Roche Pharmaceuticals, based in Basel, Switzerland. Dr. Garrison received a BA in Economics from Indiana University, and a PhD in Economics from Stanford University. He has more than 180 publications in peer-reviewed journals. Dr. Garrison was elected as ISPOR President for July 2016-June 2017. He is currently serving as co-chair of ISPOR’s Policy Outlook Committee for the Health Science Policy Council.

ABOUT OHE

Founded in 1962, the Office of Health Economics (OHE) is the world’s oldest health economics research organisation. Since 2016, OHE has been a charity (not-for-profit) and in 2019 it was awarded Independent Research Organisation status by the UK government (BEIS) placing it on an equal footing with UK Higher Education Institutions. As well as conducting research in the economics of the health and life sciences sectors, OHE provides consulting and advisory services to companies, trade associations and governments around the world.